Even if we have not recruited a control group, the reduction of AT1 receptor expression after rosuvastatin treatment could be explained by a specific effect of diabetes, given that the two groups didn’t differ in their lipid profile. The gene discussed is AGTR1; the disease is diabetes mellitus.